Literature DB >> 15982996

A survey of the off-label use of mood stabilizers in a large psychiatric hospital.

Camilla Haw1, Jean Stubbs.   

Abstract

The term 'off-label' prescribing refers to the use of a drug outside the terms of its Marketing Authorization, including prescribing for an unlicensed indication. The aims of the study were to determine the frequency of off-label prescriptions for mood stabilizers (lithium and antiepileptics) among inpatients of a large psychiatric hospital, the nature of the off-label clinical indications in use and whether patients had been informed about the off-label usage.A cross-sectional survey of inpatients aged 18-65 years at St Andrew's Hospital, Northampton, UK and interviews with consultant psychiatrists about off-label usage of mood stabilizers were carried out. Of the 249 patients studied, 75 (30.1%) were receiving one or more mood stabilizers, of which 71 (94.7%) were off-label. The most frequently cited off-label indications for mood stabilizers were: prophylaxis of mood swings (48 cases), treatment of aggression (31), manic symptoms (10), antipsychotic augmentation in treatment-resistant schizophrenia (7) and post-traumatic stress disorder (6). Lithium was prescribed infrequently. The reasons for this are discussed. Although in most instances the psychiatrist was aware the drug was being used off-label, in less than one-third of cases had the patient been informed of this, partly because of anticipated difficulties in their understanding the off-label concept, but also because of concerns that this information could adversely affect compliance. The off-label prescription of mood stabilizers is very common in psychiatry and such usage benefits patients. When prescribing off-label, psychiatrists should consider the evidence that the drug is likely to be effective for the unlicensed indication. Where there is limited evidence of benefit, a trial of the drug, with clinical monitoring, may be indicated. Patients should be fully informed about their medication, and this includes information that the prescription is off-label. Pharmacists can assist this process. The off-label concept may be difficult for some patients to understand.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982996     DOI: 10.1177/0269881105053307

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

1.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

2.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

3.  Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  J Psychosom Res       Date:  2013-07-26       Impact factor: 3.006

4.  Correlates and psychiatric disorders associated with psychotropic drug use in Taiwan.

Authors:  I-Chia Chien; Shin-Huey Bih; Ching-Heng Lin; Yiing-Jenq Chou; Wen-Guang Lee; Cheng-Hua Lee; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-20       Impact factor: 4.328

5.  Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.

Authors:  Christine Fukada; Jillian Clare Kohler; Heather Boon; Zubin Austin; Murray Krahn
Journal:  Can Pharm J (Ott)       Date:  2012-11

6.  Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.

Authors:  Gudrun Hefner; Jan Wolff; Sermin Toto; Pamela Reißner; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2022-09-07       Impact factor: 3.850

7.  Clinical characteristics and unlicensed applications of licensed psychotropic drugs within a regional tertiary service for patients with affective disorders.

Authors:  Nupur Tiwari; David S Baldwin
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-23

8.  Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release.

Authors:  Elizabeth Scarr; Brian Dean
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-04-30       Impact factor: 2.582

9.  Off-label use of sodium valproate for schizophrenia.

Authors:  Einav Horowitz; Lisa Carroll Bergman; Charna Ashkenazy; Irit Moscona-Hurvitz; Haya Grinvald-Fogel; Racheli Magnezi
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

10.  Antipsychotics, mood stabilisers, and risk of violent crime.

Authors:  Seena Fazel; Johan Zetterqvist; Henrik Larsson; Niklas Långström; Paul Lichtenstein
Journal:  Lancet       Date:  2014-05-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.